Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
about
Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma.Evaluation of the prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers.Increased intraepithelial CD3+ T-lymphocytes and high PD-L1 expression on tumor cells are associated with a favorable prognosis in esophageal squamous cell carcinoma and allow prognostic immunogenic subgrouping.Recent developments in the use of immunotherapy in non-small cell lung cancer.PD1 and PDL1 expression in primary central nervous system diffuse large B-cell lymphoma are frequent and expression of PD1 predicts poor survival.Immune Checkpoint Inhibitors for Brain Metastases.Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients.Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor NivolumabStromal and intraepithelial tumor-infiltrating lymphocytes in colorectal carcinoma.CD274 (PDL1) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients.Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors.NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.Molecular and clinical features of the TP53 signature gene expression profile in early-stage breast cancer.APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway.VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.Immunotherapy in the Asiatic population: any differences from Caucasian population?
P2860
Q37295612-1E92E9C8-F28C-4F70-862F-0B24FDC2461DQ37536901-E197EEA1-67F8-4019-9A11-FCCF01035185Q38704949-ECBAC8E6-E002-4B22-A6D6-5C371C72176CQ38826419-12A9CE8A-146A-4207-9D35-32FB5A4744D4Q39102913-93D87D39-DFBA-4AF1-BE26-F66C34B32407Q39247421-4B8C2585-A530-49A3-A6FF-B4A6444969CDQ41201725-EEC41565-42C5-427E-9D83-67D9E56CF990Q41333886-D73F8F90-71CB-4900-9495-395B666938CFQ47123925-43B407D7-97A7-4E75-B430-E696BD87B752Q48262038-FC7AE24D-1F34-4D60-BF21-D4FC43902C60Q50089792-520A1A2A-3858-48B3-A966-87076516AC00Q51065844-91006DF8-5FEC-4991-9B1B-461475F006C8Q51759206-49B285F1-7425-492D-B1F2-82EB5F09C2EBQ52562762-F39B8C92-538C-478C-B61E-077EEDFA54F0Q52630284-12CC9B55-B1C5-4F13-B37B-3DCE654AB7F9Q55020853-70F863C6-5354-4B80-ADFE-1D3004D638B4Q55312983-07FE9DDF-4580-4013-AE13-B44C91D41B83
P2860
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
@en
type
label
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
@en
prefLabel
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.
@en
P2093
P2860
P1433
P1476
Potential biomarker for checkpoint blockade immunotherapy and treatment strategy
@en
P2093
Ri-Qiang Liao
Shu-Mei Huang
Yi-Long Wu
P2860
P2888
P304
P356
10.1007/S13277-016-4812-9
P50
P577
2016-01-16T00:00:00Z
P6179
1053257403